vTv Therapeutics (VTVT) Revenue & Revenue Breakdown
vTv Therapeutics Revenue Highlights
00
Main Segment (Y)
Reportable Segment
vTv Therapeutics Revenue by Period
vTv Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2025-12-31 | - | -100.00% |
| 2024-12-31 | $1.02M | 100.00% |
| 2023-12-31 | - | -100.00% |
| 2022-12-31 | $2.02M | -49.61% |
| 2021-12-31 | $4.00M | -37.56% |
| 2020-12-31 | $6.41M | 132.05% |
| 2019-12-31 | $2.76M | -77.77% |
| 2018-12-31 | $12.43M | 4172.85% |
| 2017-12-31 | $291.00K | -54.10% |
| 2016-12-31 | $634.00K | 22.16% |
| 2015-12-31 | $519.00K | -66.49% |
| 2014-12-31 | $1.55M | 58.71% |
| 2013-12-31 | $976.00K | - |
vTv Therapeutics generated - in revenue during NA 2025, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
vTv Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2026-06-30 | - | -100.00% |
| 2026-03-31 | $36.84M | 100.00% |
| 2025-12-31 | - | 100.00% |
| 2025-09-30 | - | 100.00% |
| 2025-06-30 | - | 100.00% |
| 2025-03-31 | - | -100.00% |
| 2024-12-31 | $17.00K | 100.00% |
| 2024-09-30 | - | 100.00% |
| 2024-06-30 | - | -100.00% |
| 2024-03-31 | $1.00M | 100.00% |
| 2023-12-31 | - | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | -100.00% |
| 2022-12-31 | $9.00K | 100.00% |
| 2022-09-30 | - | -100.00% |
| 2022-06-30 | $9.00K | -99.55% |
| 2022-03-31 | $2.00M | 22122.22% |
| 2021-12-31 | $9.00K | -99.70% |
| 2021-09-30 | $3.00M | 33233.33% |
| 2021-06-30 | $9.00K | -99.09% |
| 2021-03-31 | $987.00K | -84.58% |
| 2020-12-31 | $6.40M | 91314.29% |
| 2020-09-30 | $7.00K | 100.00% |
| 2020-06-30 | - | -100.00% |
| 2020-03-31 | $8.00K | 14.29% |
| 2019-12-31 | $7.00K | -12.50% |
| 2019-09-30 | $8.00K | -99.56% |
| 2019-06-30 | $1.83M | 98.48% |
| 2019-03-31 | $921.00K | -79.63% |
| 2018-12-31 | $4.52M | 33.99% |
| 2018-09-30 | $3.38M | 36.47% |
| 2018-06-30 | $2.47M | 19.82% |
| 2018-03-31 | $2.06M | 785.84% |
| 2017-12-31 | $233.00K | 1453.33% |
| 2017-09-30 | $15.00K | 15.38% |
| 2017-06-30 | $13.00K | -56.67% |
| 2017-03-31 | $30.00K | -21.05% |
| 2016-12-31 | $38.00K | - |
| 2016-09-30 | $38.00K | -79.12% |
| 2016-06-30 | $182.00K | -51.60% |
| 2016-03-31 | $376.00K | 66.37% |
| 2015-12-31 | $226.00K | 69.92% |
| 2015-09-30 | $133.00K | 20.91% |
| 2015-06-30 | $110.00K | 120.00% |
| 2015-03-31 | $50.00K | -94.65% |
| 2014-12-31 | $934.00K | 133.50% |
| 2014-09-30 | $400.00K | 99.00% |
| 2014-06-30 | $201.00K | 1335.71% |
| 2014-03-31 | $14.00K | - |
vTv Therapeutics generated - in revenue during Q2 2026, up -100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
vTv Therapeutics Revenue Breakdown
vTv Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 24 |
|---|---|
| Reportable Segment | $1.00M |
Latest
vTv Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 24: Reportable Segment (100.00%).
Quarterly Revenue by Product
| Product/Service | Jun 26 | Mar 26 |
|---|---|---|
| Reportable Segment | $36.80M | $36.80M |
Latest
vTv Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Jun 26: Reportable Segment (100.00%).
vTv Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| OTLK | Outlook Therapeutics | $1.41T | $9.00K |
| FBIO | Fortress Biotech | $61.24M | $17.84M |
| CRVO | CervoMed | $4.01M | - |
| NRXP | NRx Pharmaceuticals | $1.23M | $1.10M |
| OSTX | OS Therapies | - | - |
| INKT | MiNK Therapeutics | - | - |
| SPRB | Spruce Biosciences | - | - |
| VTVT | vTv Therapeutics | - | - |
| IOBT | IO Biotech | - | - |
| GANX | Gain Therapeutics | - | - |
| HOWL | Werewolf Therapeutics | - | $21.00M |